Barclays analyst Andrew Mok lowered the firm's price target on Tenet Healthcare to $238 from $257 and keeps an Overweight rating on the shares post the Q1 report. The company "exhibited its ability to flex the acute cost structure" given volume headwinds, the analyst tells investors in a research note. Barclays believes Tenet's full year Affordable Car Act headwind assumption will ultimately prove conservative.
